GlassScriptPhysician profile
Robert T Casimir
NPI 1073731691
$2,843.12
in general payments reported to CMS, 2019-2025
16 companies · $102 in 2025
The $102 reported for 2025 was more than what a typical Anesthesiology provider received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $143 · 2020: $1,086 · 2021: $365 · 2022: $495 · 2023: $653 · 2025: $102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $755.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $754.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $614.34 | 2022-2023 | Ascenda, Strata |
| Medtronic USA, INC. | $391.60 | 2020 | |
| Genesys Orthopedics Systems, L.L.C. | $375.77 | 2020-2021 | |
| Avanos Medical | $253.66 | 2019-2021 | |
| Eagle Pharmaceuticals, INC. | $249.96 | 2023 | |
| Bioventus LLC | $161.35 | 2022 | |
| Abbott Laboratories | $153.60 | 2021 | |
| Orthofix Medical, INC. | $143.64 | 2020 | |
| Acacia Pharma INC | $123.10 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $122.04 | 2023 | Fasenra |
| Gilead Sciences, INC. | $105.60 | 2020 | |
| Tonix Medicines, INC. | $84.05 | 2025 | |
| Arbor Pharmaceuticals, INC. | $17.83 | 2021 | |
| Averitas Pharma INC. | $17.82 | 2025 | Qutenza |
| Pacira Pharmaceuticals Incorporated | $17.66 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hydrocision, INC. | $11.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Casimir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.